These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10530416)

  • 1. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
    Pati HP; Choudhry VP
    Eur J Haematol; 1999 Oct; 63(4):267-8. PubMed ID: 10530416
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
    Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
    Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y; Nisli G; Kavakli K
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
    El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F
    Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
    Dadheech S; Rao AV; Shaheen U; Hussien MD; Jain S; Jyothy A; Munshi A
    Gene; 2013 Dec; 531(2):301-5. PubMed ID: 24036429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 11. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G; Lindeman R
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract]   [Full Text] [Related]  

  • 12. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM; Nathan DG; Olivieri NF; Pippard MJ; Weatherall DJ
    Lancet; 2003 Jan; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract]   [Full Text] [Related]  

  • 13. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ; Kolnagou A
    Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
    Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron chelation with oral deferiprone in patients with thalassemia.
    Wonke B; Telfer P; Hoffbrand AV
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 20. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
    Musallam KM; Taher AT
    Haematologica; 2011 Feb; 96(2):e5-6; author reply e7-8. PubMed ID: 21282714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.